

March 2017

Nuplazid

INDICATION: NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

DAILY DOSING: Recommended dose is 34 mg, taken orally as two 17 mg tablets once daily, without titration. Can be taken with or without food.

WARNINGS: **INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS**
See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

WARNINGS AND PRECAUTIONS:

- ✓ QT Interval Prolongation: Increases in QT interval; avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval.
- ✓ Most common adverse reactions (>5% and twice the rate of placebo): peripheral edema and confusional state.

DRUG INTERACTIONS:

- ✓ **Strong CYP3A4 Inhibitor** (e.g. Ketaconazole) Reduce Nuplazid Dose by one-half.
Examples: Class 1A antiarrhythmics: quinidine, procainamide, disopyramide;
Class 3 antiarrhythmics: amiodarone, sotalol;
Antipsychotics: ziprasidone, chlorpromazine, thioridazine;
Antibiotics: gatifloxacin, moxifloxacin
- ✓ **Strong CYP3A4 inducers:** Monitor for reduced efficacy. Increase in Nuplazid dosage may be needed.
Examples: rifampin, carbamazepine, phenytoin, St. John's wort

USE IN SPECIFIC POPULATIONS:

- ✓ Renal Impairment: No dosage adjustment for Nuplazid is needed in patients with mild to moderate renal impairment. Use of Nuplazid is NOT recommended in patients with severe renal impairment.
- ✓ Hepatic Impairment: Use of Nuplazid is NOT recommended in patients with hepatic impairment.

Drugs Having No Clinically Important Interactions with NUPLAZID: Based on pharmacokinetic studies, no dosage adjustment of carbidopa/levodopa is required when administered concomitantly with NUPLAZID.

HOW SUPPLIED/STORAGE AND HANDLING: **17 mg Tablet:** White to off-white, round, coated tablet debossed with "P" on one side and "17" on the reverse.

Storage: Store at 20°C to 25°C (68°F to 77°F)

References: Nuplazid Available at www.nuplazid.com/Patients/Caregivers
PLEASE refer to Medication Guide for Complete information